Patents by Inventor Herbert C. Hoover, Jr.

Herbert C. Hoover, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumor associated epitope
    Patent number: 5951985
    Abstract: This invention relates to the epitopes to which monoclonal antibody 88BV59 and antibody 16.88 react. These antibodies were produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigens. Both epitopes are found on the same antigen in tumor tissue. These epitopes can be used in both diagnostic procedures and therapy for human cancers.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: September 14, 1999
    Assignee: Perimmune Holdings, Inc.
    Inventors: Sandra M. Butler, Nicholas Pomato, Ebo Bos, Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
  • Active specific immunotherapy
    Patent number: 5484596
    Abstract: This invention relates to a method of cancer therapy for treating human patients with resectable solid tumors to inhibit recurrence and formation of metastases, comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, irradiating the tumor cells to be viable but non-tumorigenic, preparing a vaccine comprising about 10.sup.7 viable but non-tumorigenic tumor cells per dose and injecting the vaccine intradermally into the human patient after the patient's immune system has recovered from surgery.
    Type: Grant
    Filed: November 1, 1993
    Date of Patent: January 16, 1996
    Assignee: Akzo N.V.
    Inventors: Michael G. Hanna, Jr., Herbert C. Hoover, Jr., Leona C. Peters
  • Tumor associated monoclonal antibodies
    Patent number: 5474755
    Abstract: This invention relates to monoclonal antibody 88BV59 produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: December 12, 1995
    Assignee: Akzo Nobel N.V.
    Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr., Marie E. Dembinsky, Barry J. Kobrin
  • Tumor associated monoclonal antibody 81AV/78
    Patent number: 5348880
    Abstract: This invention relates to human monoclonal antibody 81AV78 produced by a transformed B-cell line, having ATCC accession number CRL 10750 derived from B-cells of cancer patients actively immunized with autologous tumor antimen. This monoclonal antibody can be used in both diagnostic procedures and therapy for human cancers.
    Type: Grant
    Filed: July 20, 1993
    Date of Patent: September 20, 1994
    Assignee: Akzo N.V.
    Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
  • Tumor specific monoclonal antibodies
    Patent number: 5180814
    Abstract: A human monoclonal antibody having specificity for an epitope in a tumor associated antigen, said antibody produced by a cell line selected from the group consisting of Co6a3-1 (HB8493), Co7a4 (HB8494), Co28A32 (HB9380), Co16-86 (HB8496), and Co16-88 (HB8495).
    Type: Grant
    Filed: January 22, 1991
    Date of Patent: January 19, 1993
    Assignee: Akzo N.V.
    Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
  • Tumor specific monoclonal antibodies
    Patent number: 5106738
    Abstract: A method for producing a human B-lymphocyte that is able to grow in cell culture and produces human monoclonal antibodies having binding specificity for tumor-associated antigens by exposing a human B-lymphocyte to a tumor cell antigen in a vaccine containing viable human tumor cells that have been made non-tumorigenic, and immortalizing the exposed B-lymphocyte by exposing to a transforming agent for sufficient time to transform the B-lymphocyte.
    Type: Grant
    Filed: January 25, 1989
    Date of Patent: April 21, 1992
    Assignee: AKZO NV
    Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Jr., Herbert C. Hoover, Jr.
  • Tumor associated monocoloal antibodies derived from human B-cell line
    Patent number: 4997762
    Abstract: Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.
    Type: Grant
    Filed: April 15, 1987
    Date of Patent: March 5, 1991
    Assignee: Akzo N.V.
    Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
  • Tumor specific monoclonal antibodies
    Patent number: 4828991
    Abstract: Monoclonal antibodies produced by hybridoma or transformed B-cell lines deriveed from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.
    Type: Grant
    Filed: January 31, 1985
    Date of Patent: May 9, 1989
    Assignee: Akzo N.V.
    Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.